Oasmia Pharmaceutical AB (OASM.ST) WACC Analysis

As of May 27, 2025, Oasmia Pharmaceutical AB (OASM.ST) carries a Weighted Average Cost of Capital (WACC) of 7.3%. WACC reflects the blended rate Oasmia Pharmaceutical AB must pay to both equity and debt holders.

Within that, the cost of equity is 5.2%, the cost of debt is 7.0%, and the effective tax rate is 0.0%.

Breakdown of WACC Components

• Long-term bond rate: 0.6% – 1.1%
• Equity market risk premium: 5.2% – 6.2%
• Adjusted beta: 0.49 – 0.94
• Additional risk adjustment: 2.0% – 2.5%
• Debt-to-equity ratio: 0.07

What It Means for Investors

With a selected WACC of 7.3%, Oasmia Pharmaceutical AB must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.